Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Sprinklr in a note issued ...

William Blair cut their Q1 2025 earnings per share (EPS) estimates for Arcturus Therapeutics in a report issued on Thursday, March 13th. William Blair analyst M. Minter now forecasts that the ...

We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...

Fintel reports that on March 12, 2025, William Blair downgraded their outlook for Udemy (NasdaqGS:UDMY) from Outperform to ...

William Blair downgraded Udemy (UDMY) to Market Perform from Outperform after the company announced the appointment of Hugo Sarrazin as ...

In a report released today, Ross Sparenblek from William Blair maintained a Buy rating on MSA Safety (MSA – Research Report). The company’s ...

JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...

The firm upgraded Palantir from Underperform to Market Perform after a sharp stock decline but did not assign a price target.

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Palantir (NASDAQ:PLTR) was upgraded to Market Perform from Underperform by William Blair, following the recent share price ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

The embedded finance company, which posted a loss last year, hired Citi to explore its strategic options and named an interim ...